Cardiology overview prevention: Difference between revisions
Jump to navigation
Jump to search
Created page with "{{Cardiology overview}} {{CMG}} ==References== {{Reflist|2}} {{WS}} {{WH}}" |
No edit summary |
||
| Line 1: | Line 1: | ||
{{Cardiology overview}} | {{Cardiology overview}} | ||
{{CMG}} | {{CMG}} | ||
==Statin Therapy== | |||
===Drug Interactions=== | |||
*[[Cyclosporin]] co-administration is associated with a higher rate of [[myositis]] among statin users as a result of inhibition of [[CYP3A4]]. The exception is [[pravastatin]] in which this is not a problem. | |||
==References== | ==References== | ||
Revision as of 15:48, 31 October 2011
|
Cardiology Overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Statin Therapy
Drug Interactions
- Cyclosporin co-administration is associated with a higher rate of myositis among statin users as a result of inhibition of CYP3A4. The exception is pravastatin in which this is not a problem.